Immupharma (IMM)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

6.36p
   
  • Change Today:
    -0.44p
  • 52 Week High: 17.60
  • 52 Week Low: 1.50
  • Currency: UK Pounds
  • Shares Issued: 502.72m
  • Volume: 4,073,271
  • Market Cap: £31.97m
  • RiskGrade: 328
  • Beta: 1.22

Deal with Barclays    Trade now with Barclays Stockbrokers

Immupharma Overview

ImmuPharma PLC is a pharmaceutical development company focusing on developing novel medicines in specialist markets with serious unmet need. Lupuzor™ is the company’s most advanced drug in development and is a treatment for lupus, a life threatening autoimmune disease and has now completed dosing Lupus patients in its Phase III pivotal trial. This is only part of our story as our scientists and researchers are developing drugs to make life changing difference to peoples lives worldwide.
Registrars: Computershare Investor Services PLC

Key Personnel

CEO: Timothy Paul McCarthy
Chief Operating Officer: Tim Franklin
Chief Science Officer: Sébastien Goudreau
Independent Non-Executive Director: Ketan Patel
Senior Independent Non-Executive Director: Laurence Reilly
Non-Executive Dir: Lisa Baderoon

Contact Details

Address: One Bartholomew Close, London, United Kingdom, EC1A 7BL
Phone: +44 20 7206 2650
Fax: +44 20 7152 4001
Website: http://www.immupharma.co.uk/

Listings

Sector: Pharma and Biotech(LSE)
Index: FTSE AIM All-Share
Domestic Listings: LSE:4GUK
ISIN: GB0033711010

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Immupharma Market Data

Currency UK Pounds
Share Price 6.36p
Change Today -0.44p
% Change -6.47 %
52 Week High 17.60
52 Week Low 1.50
Volume 4,073,271
Shares Issued 502.72m
Market Cap £31.97m
Beta 1.22
RiskGrade 328

Immupharma Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average29.39% below the market average
21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average21.95% above the sector average
Price Trend
67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average67.97% below the market average
40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average40.91% below the sector average
Income Not Available
Growth Not Available

Immupharma Dividends

No dividends found

Trades for 30-Jan-2026

Time Volume / Share Price
15:03 234,558 @ 6.40p
15:44 120,000 @ 6.33p
16:26 50,000 @ 6.33p
16:22 77,167 @ 6.46p
16:10 9,164 @ 6.46p

Immupharma Key Personnel

CEO Timothy Paul McCarthy

Top of Page